TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03338621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: 200 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: 200 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: 100 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: 100 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: 500 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: 500 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HRZE
Description: isoniazid 75 mg plus rifampicin 150 mg plus pyrazinamide 400 mg plus ethambutol 275 mg combination tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HR
Description: isoniazid 75 mg plus rifampicin 150 mg combination tablets
Study: NCT03113123

Intervention type: DRUG
Group type: OTHER
Intervention: PrEP with Truvada®
Description: Associated with:~* STD screening/treatment for syphilis, gonorrhoea and chlamydiae~* HIV screening/therapy~* Questionnaire~* Addiction, social or psychological follow-up care if needed~* Peer interactive counselling (peer counselors/nurses/physicians experienced with therapeutic education) at the baseline visit and at every follow-up visit up to 6 months. After 6 months, counselling will be provided at the request of participants if they need it. Counselors will remain in contact with the participants between visit to answer any questions relative to PrEP, treatment and prevention, and to facilitate participants interactions with study sites.
Study: NCT03940963

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AxoGuard® Nerve Cap
Description: Entubulation of the nerve stump into the AxoGuard® Nerve Cap following surgical excision of symptomatic neuroma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Neurectomy
Description: Surgical excision of symptomatic neuroma
Study: NCT02080104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intarvenous and intramusculer 10 IU oxytocin
Description: intarvenous and intramusculer 10 IU oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intarvenous and intramusculer 10 IU oxytocin
Description: intarvenous and intramusculer 10 IU oxytocin
Study: NCT02013336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
Description: chemotherapy
Study: NCT01682993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topography guided Excimer Laser treatment and Corneal Cross Linking
Description: A topography guided excimer laser treatment will be performed prior to CCL in one session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corneal Cross Linking
Description: A standard corneal cross linking procedure will be performed in this arm.
Study: NCT02635074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV
Study: NCT01148862

Intervention type: DEVICE
Group type: OTHER
Intervention: The MiniMed Paradigm® X54 System
Description: The MiniMed Paradigm® X54 System: A insulin pump equipped with a number of features to actively manage the user's glucose levels. One example is the Low Glucose Suspend (LGS) feature. The LGS feature is only available when the pump is used with the subcutaneous glucose sensor for continuous glucose monitoring. To use this feature, the user will be required to select a sensor low suspend limit, or threshold, at which the LGS feature will be triggered. When this feature is selected, if the sensor glucose reading reaches the level that is equal to or less than the programmed threshold, the user receives an alert and the pump suspends.

Intervention type: DEVICE
Group type: OTHER
Intervention: The MiniMed Paradigm® X54 System
Description: The MiniMed Paradigm® X54 System: A insulin pump equipped with a number of features to actively manage the user's glucose levels. One example is the Low Glucose Suspend (LGS) feature. The LGS feature is only available when the pump is used with the subcutaneous glucose sensor for continuous glucose monitoring. To use this feature, the user will be required to select a sensor low suspend limit, or threshold, at which the LGS feature will be triggered. When this feature is selected, if the sensor glucose reading reaches the level that is equal to or less than the programmed threshold, the user receives an alert and the pump suspends.
Study: NCT00621868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: Oral
Study: NCT04531371

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine injection
Description: post surgical agitation prophylaxis
Study: NCT03211897

Intervention type: DRUG
Intervention: Haloperidol Injection
Description: As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive haloperidol as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
Study: NCT00621868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT02939300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: * Melanoma:~  - Combination therapy with Nivolumab 1 mg/kg for 4 doses followed by monotherapy Nivolumab 480 mg per cycle.~* Non-small Cell Lung Cancer / Head and Neck Cancer:~  - Combination therapy with Nivolumab 3 mg/kg~* Small Cell Lung Cancer / Breast Cancer / Bladder Cancer:~  - Combination therapy with Nivolumab 1 mg/kg for 4 doses followed by monotherapy Nivolumab 240 mg per cycle.~* Renal Cell Carcinoma / Other Solid Tumors (not listed above):~  * Combination therapy with Nivolumab 3 mg/kg for 4 doses followed by monotherapy Nivolumab 480 mg per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: * Non-small Cell Lung Cancer / Head and Neck Cancer:~  - Combination therapy with Ipilimumab 1 mg/kg~* Small Cell Lung Cancer / Breast Cancer / Bladder Cancer:~  - Combination therapy with Ipilimumab 3 mg/kg for 4 doses~* Renal Cell Carcinoma / Other Solid Tumors (not listed above):~  * Combination therapy with Ipilimumab 3 mg/kg for 4 doses
Study: NCT00535782

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tocilizumab
Description: Administered by intravenous infusion, 8 mg/kg every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Administered by intravenous infusion, 8 mg/kg every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to tocilizumab administered by intravenous infusion every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Administered orally or parenterally, 7.5-25 mg weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally or parenterally, 7.5-25 mg weekly.
Study: NCT02023411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: recombinant human parathyroid hormone (1-34) subcutaneous every day at 8-9 pm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04257123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelesis100
Description: Participants will administer Gelesis100 before lunch and dinner meals.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelesis100
Description: Participants will administer Gelesis100 before lunch and dinner meals.
Study: NCT04352166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended-release buprenorphine (BXR)
Description: Three monthly injections will be provided during the course of the 12 week trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sublingual buprenorphine (BSL)
Description: On a weekly basis patients will be provided with sublingual buprenorphine to take up to 24 mg daily.
Study: NCT02123758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Administered orally (by mouth) once daily in morning at a dose of 1000 mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Administered orally (by mouth) once daily in morning at a dose of 1000 mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered orally twice a day at a dose of 5mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered orally twice a day at a dose of 5mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927
Description: Administered orally once daily in morning at a dose of 240 mg starting on Day 8, Treatment Cycle 1 for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927
Description: Administered orally once daily in morning at a dose of 240 mg starting on Day 8, Treatment Cycle 1 for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
Study: NCT01209871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine
Description: Given ID

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03593590

Intervention type: DRUG
Intervention: Ocrelizumab
Description: Ocrelizumab is administered as an intravenous infusion in accordance with the approved labelling.
Study: NCT04257123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will administer a placebo before lunch and dinner meals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will administer a placebo before lunch and dinner meals.
Study: NCT03643601

Intervention type: OTHER
Intervention: Non-Interventional
Description: Epidemiological overview of CKD-associated anemia and treatment patterns, rather than to evaluate specific drugs

Intervention type: OTHER
Intervention: Non-Interventional
Description: Epidemiological overview of CKD-associated anemia and treatment patterns, rather than to evaluate specific drugs
Study: NCT00585832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH-4-Teens
Description: 24-week behavioral nutrition intervention emphasizing a diet high in fruits, vegetables and low fat dairy foods and that is low in fat and sodium
Study: NCT02974881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Mitral Valve Replacement
Description: Minimally invasive transcatheter mitral valve implantation using the HighLife™ TMVR system
Study: NCT01908465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ebastine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03211897

Intervention type: DRUG
Intervention: Ziprasidone Injection
Description: As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive ziprasidone as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
Study: NCT02721576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Glycididazole
Description: Sodium Glycididazole 800mg/m2.Three times a week (once every other one day),before radiation therapy, total 5-6 weeks.
Study: NCT03211897

Intervention type: DRUG
Intervention: OLANZapine Injection
Description: As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive olanzapine as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.

Intervention type: DRUG
Intervention: Midazolam injection
Description: As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive midazolam as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
Study: NCT01490125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 110/50 μg hard non-gelatin capsule, inhalation/blister once a day via SDDPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18 ug hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to QVA149
Description: Placebo 0 mg hard non-gelatin capsule, inhalation/ blister once a day via SDDPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to QVA149
Description: Placebo 0 mg hard non-gelatin capsule, inhalation/ blister once a day via SDDPI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to tiotropium
Description: Placebo 0 mg hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to tiotropium
Description: Placebo 0 mg hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol/albuterol
Description: salbutamol/albuterol (containing CFC-free propellant -HFA 134a) inhaler used as rescue medication when needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol/albuterol
Description: salbutamol/albuterol (containing CFC-free propellant -HFA 134a) inhaler used as rescue medication when needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol/albuterol
Description: salbutamol/albuterol (containing CFC-free propellant -HFA 134a) inhaler used as rescue medication when needed.
Study: NCT00585832

Intervention type: OTHER
Group type: OTHER
Intervention: Routine Care
Description: individual in-person counseling sessions on guidelines consistent with the Fourth Pediatric Report of the National High Blood Pressure Education Program.
Study: NCT01983943

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol, the active ingredient in olive oil.
Description: A 40mg capsule will be taken once daily for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 40mg placebo will be taken once per day for 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition counseling
Description: Nutrition counseling on eating a healthy diet will be offered once at baseline.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition counseling
Description: Nutrition counseling on eating a healthy diet will be offered once at baseline.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endopat
Description: An endopat test will be administered twice, once and baseline and once after 6 months of supplementation, to test endothelial function. This is a non-invasive test that takes about 15 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Endopat
Description: An endopat test will be administered twice, once and baseline and once after 6 months of supplementation, to test endothelial function. This is a non-invasive test that takes about 15 minutes.
Study: NCT00003620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04056845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valgus knee brace (Medex K39-OA Corrector)
Description: Valgus knee brace given to patients as part of the conservative management for knee osteoarthritis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy and oral analgesic (diclofenac and panadol)
Description: Physiotherapy and oral analgesic (diclofenac and panadol)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy and oral analgesic (diclofenac and panadol)
Description: Physiotherapy and oral analgesic (diclofenac and panadol)
Study: NCT00714012

Intervention type: OTHER
Intervention: observational
Description: presented with paper-based sets, web based sets or human simulator based set of questionnaires designed to identify the users' experience level and optimal visual or auditory elements for each specific domain.
Study: NCT01639404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Administration
Description: The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Rehabilitation
Description: All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
Study: NCT02038855

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Intervention for Dual Problems and Early Action
Description: Integrated Intervention for Dual Problems and Early Action (IIDEA) includes psycho-education, Cognitive Behavioral Therapy and mindfulness; identifies triggers and challenging thoughts; provides motivational techniques for reducing substance use and/or smoking cravings; incorporates cognitive restructuring to identify and correct negative thinking patterns influenced by depression, anxiety and/or trauma; and includes self-monitoring of thoughts and risk behaviors that contribute to substance use, smoking and increased HIV risk.
Study: NCT03441802

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High quality extra virgin olive oil
Description: Cases and controls were given 40 g/die high quality extra virgin olive oil

Intervention type: OTHER
Group type: OTHER
Intervention: High quality extra virgin olive oil
Description: Cases and controls were given 40 g/die high quality extra virgin olive oil
Study: NCT00278070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine oral formulation
Description: Patients will take three times a week \[Monday, Wednesday and Friday\] by mouth, a standard dose of soft capsules of vinorelbine given at dose ascribed by randomization procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine oral formulation
Description: Patients will take three times a week \[Monday, Wednesday and Friday\] by mouth, a standard dose of soft capsules of vinorelbine given at dose ascribed by randomization procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine oral formulation
Description: Patients will take three times a week \[Monday, Wednesday and Friday\] by mouth, a standard dose of soft capsules of vinorelbine given at dose ascribed by randomization procedure
Study: NCT00525525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients are given 10 mg/kg IV Q2 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Patients are given 10 mg/kg IV Q2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: Patients receive 150 mg PO daily. If patients are not experiencing intolerable toxicity, they may escalate their dose to 200 mg PO daily. If patients are experiencing intolerable toxicity, their dose will be held until the toxicity improves or resolves, then re-treated at a lower dose level, i.e. 100 mg PO daily.

Intervention type: DRUG
Group type: OTHER
Intervention: Tarceva
Description: Patients receive 150 mg PO daily. If patients are not experiencing intolerable toxicity, they may escalate their dose to 200 mg PO daily. If patients are experiencing intolerable toxicity, their dose will be held until the toxicity improves or resolves, then re-treated at a lower dose level, i.e. 100 mg PO daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients receive 200 mg/m2 for Days 1-5 of every 28 day cycle. Although the calendar days may be slightly altered, the patient should always receive this dose for 5 days within a treatment cycle. If the patient experiences certain toxicities specified in the protocol, Temodar will be held then given at a reduced dose, i.e. 150 mg/m2 Days 1-5.

Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: Patients receive 200 mg/m2 for Days 1-5 of every 28 day cycle. Although the calendar days may be slightly altered, the patient should always receive this dose for 5 days within a treatment cycle. If the patient experiences certain toxicities specified in the protocol, Temodar will be held then given at a reduced dose, i.e. 150 mg/m2 Days 1-5.
Study: NCT02020525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: restrictive transfusion strategy
Description: Patients allocated to the restrictive transfusion strategy were transfused only when their hemoglobin concentration decreased below 7.7 g d dL-1 and were then maintained at hemoglobin concentrations between 7.7 and 9.9 g d dL-1.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liberal transfusion strategy
Description: Patients assigned to the liberal strategy were transfused when their hemoglobin concentration fell below 9.9 g dL-1, aiming at maintaining hemoglobin at or above 10 g dL-1.
Study: NCT05633849

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SMP group
Description: Participants were instructed to take two 500 mg softgels of LIPINOVA(SPM group) after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Participants were instructed to take two 500 mg softgels of olive oil placebo after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks